clinical AF" or "had atrial high rate events AHRE"). In MOST trial, AHRE were seen in almost 50% of patients treated for sinus node dysfunctionand were associated with an increased risk of stroke (1.69% per year if CHADS score>2) in ASSERT study. Nevertheless currently there are no antithrombotic recommendations for these patients. We tried to describe the different therapeutic alternatives in usual practice.
0446
Septal right ventricular lead positioning and optimized DDD pacing versus intrinsic conduction in sinus node disease: an echocardiographic study. The optimist trial Philippe Mabo (1), Daniel Gras (2), B.Degand (3), J.Dupuis (4), A.Pellissier (5), Aude Solnon (6), Erwan Donal (1) (1) CHU Rennes, Cardiologie, Rennes, Nouvelles Cliniques Nantaises, Cardiologie, Nantes, CHU Poitiers, Cardiologie, Poitiers, CHU Angers, Cardiologie, Angers, CHU Caen, Cardiologie, Caen, CHU Nantes, Cardiologie, Nantes, France Introduction: Preserved intrinsic conduction in paced sinus node disease (SND) patients seems to be associated with a better outcome when compared with apical right ventricular (RV) DDD pacing.The prospective, multicenter, randomized OPTIMIST study was designed to compare RV lead positioning in the septum to preserved intrinsic conduction in chronically paced SND patients.
Methods: SND patients with a class I indication were implanted with a DDD pacemaker (St. Jude medical), the RV lead being located in the midseptum. The algorithm VIP™ (Ventricular Intrinsic Preference) was programmed « on » in all patients at hospital discharge. After a 6 weeks observational period, patients with a ventricular pacing percentage inferior to 10% were randomized in 2 parallel groups: VIP « on » (preserved natural conduction -group 1) or « off » with AV delay optimization (RV pacing -group 2). Patients were followed every 6 months with echocardiography through 18 months. The primary endpoint was the left ventricular end-systolic diameter (LVESD) (Corelab analysis), with a non inferiority hypothesis.
Results: 216 patients mean age 76.07±9.45 were included and 167 randomized. The baseline characteristics were comparable in group 1 and 2 including left ventricular ejection fraction, LVEF (62.4±12.6 vs 64.4±8.7%), LVESD (32.7±8.5 vs 32.5±9.3mm) and 6 weeks RV pacing percentage (1.81±1.92 vs 2.15±2.07%). At the end of FU, as expected the percentage of RV pacing was significantly higher in group 2 (78.9±31.6 vs 7.9±17.4%). The LVEF was 62.3±10.1% in group 1 and 60.9±10.9% in group 2 (NS) and the LVESD was 31.9±7.23mm in group 1 and 31.26±7.21mm in group 2 (NS). The non-inferiority hypothesis was validated (p=2.572e-06 for a delta = 4.785). AF burden was not different between the 2 groups.
Conclusion:
When implanting the RV lead in the midseptum, DDD pacing with high percentage of RV capture was not associated with LV echocardiographic deterioration as compared to preserved intrinsic conduction pacing mode.
0017
Heart rate predicts long-term mortality as well as classical risk factors Florent Séguro (1), Emilie Bérard (2), Vanina Bongard (2), Jean-Bernard Ruidavets (2), Dorota Taraszkiewicz (1), Michel Galinier (3), Didier Carrié (1), Jean Ferrières (1 Background: Resting heart rate (RHR) is known as a cardiovascular risk factor (RF), correlated with hypertension, cardiac failure and coronary artery disease. The aim of this study was to assess the risk of all-cause mortality in a general population in a prediction algorithm including RHR as an independent parameter.
Methods: Our study population consisted in patients, both women and men, who had consulted from 1995 to 2011 to the Department of Preventive Cardiology (DPC) in a Southwestern French University Hospital. We excluded patients whose age was less than 30 years old and all patients with established history of ischemic heart disease. An algorithm for prediction of risk of mortality in primary prevention was built using Kaplan-Meier statistic and a Cox proportional hazards model. Conclusions: RHR can be used to predict all-cause mortality in primary prevention and might be evaluated as a simple predictive tool in current practice.
Significance of atrial fibrillation/tachycardia induced by esophageal stimulation
Béatrice Brembilla-Perrot (1), Arnaud Olivier (1), Nicolas Girerd (2), Vladimir Manenti (1), Jean Marc Sellal (1), Joseph Rizk (1) Esophageal electrophysiological study (EPS) is an easy means to evaluate the cause of palpitations in patients with negative Holter monitoring or when cardiac event monitor is not interpretable. The purpose of study was to evaluate the clinical significance and the diagnosis value of inducible atrial tachycardia or fibrillation (AF) by esophageal EPS.
Methods:
Esophageal EPS was performed in 159 patients, 72 males, 87 females, aged from 19 to 89 years (mean 56±16) with a normal ECG in sinus rhythm; 35 patients had presented one episode of documented sustained AF (group I). Remaining 124 patients had no documented AF (group II) and were studied for not documented tachycardia (n=70), not documented tachycardia associated with dizziness/syncope (n=23), unexplained stroke and salvos of AF (n=25), wide-QRS tachycardia suspected of atrial origin (n=6). Atrial pacing and programmed atrial stimulation with 1 and 2 extrastimuli were performed in control state (CS) and after infusion of isoproterenol. Patients were followed from 1 month to 13 years (mean 4±4 years).
Results: Among group I, AF was induced in 21 patients (60%). Sustained AF was induced in CS (n=50) or after isoproterenol (n= 64) in all group II patients. The follow-up indicated that 7 group I patients (21%) had recurrent AF/atrial flutter requiring ablation, 5 patients with induced AF and 2 with negative EPS (NS). Two group I patients (6%) with induced AF died from a cardiac cause. Among group II, 20 patients (16%) presented documented AF/atrial flutter and 14 of them required an ablation. Five group II patients (4%) died from a cardiac cause. The sensitivity of esophageal EPS to reproduce AF was 60%. Its positive predictive value to predict the occurrence of AF in symptomatic patients without documented AF was 16%. The positive value to predict AF and cardiac death was 24%.
Conclusions:
Despite an average sensitivity for the induction of AF in patients with documented AF, the risk of subsequent AF and/or cardiac death was relatively high in these patients and in symptomatic patients without documented AF but with induced AF. These patients require a careful follow-up. Atrial fibrillation (AF) and atrial flutter (AFL) are frequently associated. The purpose of the study was to look for the effect of antiarrhythmic drugs (AAD) on the risk of AF occurrence after radiofrequency ablation of AFL.
Methods: 1121 patients, mean age 64±12 years, were referred for AFL ablation. History, data of echocardiography, antiarrhythmic drug (AAD), were collected. Patients were followed from 3 months to 10 years (mean 2.1±2.7 years). AAD was stopped after ablation except in patients with previous AF before ablation or continued otherwise.
Results: 857 patients received an AAD (n=637) or a betablocker (n=221). 356 patients (31.7%) had a history of AF prior to AFL ablation. Patients with AF prior to ablation were more likely to be female (OR=1.35, CI=1.00-1.83, p=0.05), more likely to be treated with a class I AAD (45.5% vs 7.7%), isolated or associated with beta-blockers and more likely tended to be treated with Amiodarone (36.5% vs. 31.2%, p=0.08). After ablation, 260 (23.2%) patients experienced AF. In multivariable model, AF prior to ablation (OR=1.90, CI=1.42-2.54, p<0.001) and female gender (OR=1.77, CI=1.29-2.42, p<0.001) were associated with a higher risk of AF after ablation. In patients without prior AF, Class I AAD and Amiodarone prior to AFL ablation were independently associated with higher risk of AF after ablation (OR=2.11, CI=1.15-3.88, p=0.02 and OR=1.60, CI=1.08-2.36, p=0.02 respectively). Patients with previously diagnosed AF were more likely to be treated with a class I AAD (45.5% vs. 7.7%), isolated or associated with betablockers (data not shown), and more likely tended to be treated with Amiodarone (36.5% vs 31.2%, p=0.08).
Conclusions: AF occurrence after AFL ablation is frequent (>20%), especially in patients with a history of AF, in female patients, and in patients treated with Class I antiarrhythmics/Amiodarone prior to AFL. The risk was similar in patients treated with class I or III drug. In a patient referred for AFL ablation without known AF before AFL, treated with AAD, the follow-up should be careful because these patients appear at high risk of AF occurrence.
